ARCHIVES

Ramucirumab Improves Overall Survival, Progression-Free Survival in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 10 | October 26, 2012

Download PDF Visit The Full Archive

Related Articles

FDA Continues Bureaucratic Delays Of Cancer INDs

January 30, 1976

NCCN’s First Physician CEO: Robert Carlson Pledges Broader Research and Policy Agenda

October 5, 2012

Inspector General’s chronology Of Events In Gallo Research

July 1, 1994

ACS names new officers.

December 5, 2003

In Brief: Override Failure Would Leave Cancer Program With No Money or New Projects Of Any Kind

January 23, 1976

In Brief: Rogers On AHF Board; GAO Says Legislation May Needed For Hospice Reimbursement

March 23, 1979